Harmony Biosciences Holdings Inc Share Price Today: Live Updates & Key Insights

Harmony Biosciences Holdings Inc share price today is $28.28, up -0.32%. The stock opened at $27.56 against the previous close of $27.81, with an intraday high of $27.99 and low of $27.52.

Harmony Biosciences Holdings Inc Share Price Chart

Harmony Biosciences Holdings Inc

us-stock
To Invest in {{usstockname}}
us-stock

Harmony Biosciences Holdings Inc Share Price Performance

$28.28 -0.0032(-0.32%) HRMY at 23 Mar 2026 01:30 PM Biotechnology
Lowest Today 27.52
Highest Today 27.99
Today’s Open 27.56
Prev. Close 27.81
52 Week High 40.87
52 Week Low 25.52
Day’s Range: Low 27.52 High 27.99
52-Week Range: Low 25.52 High 40.87
1 day return -
1 Week return -0.5
1 month return +3.12
3 month return -28.71
6 month return -14.44
1 year return -19.04
3 year return -34.46
5 year return -3.81
10 year return -

Harmony Biosciences Holdings Inc Institutional Holdings

BlackRock Inc 11.97

Vanguard Group Inc 8.32

FMR Inc 5.38

iShares Core S&P Small-Cap ETF 4.17

HBM Healthcare Investments AG Ord 3.71

American Century Companies Inc 3.18

Dimensional Fund Advisors, Inc. 3.17

Avantis US Small Cap Value ETF 2.93

LSV Asset Management 2.86

State Street Corp 2.86

Arrowstreet Capital Limited Partnership 2.58

Fidelity Growth Compy Commingled Pl S 2.54

Vanguard Total Stock Mkt Idx Inv 2.49

Geode Capital Management, LLC 2.20

Valor Management LLC 2.19

Renaissance Technologies Corp 1.85

iShares Russell 2000 ETF 1.83

Vanguard Small Cap Index 1.80

Fidelity Growth Company Fund 1.74

Morgan Stanley - Brokerage Accounts 1.47

BlackRock Global Equity Mkt Netrl Instl 1.43

AQR Capital Management LLC 1.41

Boston Partners Global Investors, Inc 1.23

The Goldman Sachs Group Inc 1.12

Vanguard Small Cap Growth Index Inv 1.00

Massachusetts Financial Services Company 0.94

BNP Paribas Arbitrage, SA 0.91

UBS Group AG 0.87

Armistice Capital, LLC 0.86

venBio Partners LLC 0.85

Fidelity Small Cap Index 0.74

Vanguard Institutional Extnd Mkt Idx Tr 0.74

MFS New Discovery I 0.67

State Street SPDR Port S&P 600 Sm CpETF 0.64

iShares Russell 2000 Growth ETF 0.63

iShares S&P Small-Cap 600 Growth ETF 0.59

Invesco Pharmaceuticals ETF 0.56

Tieton Small Cap Value 0.51

Pacer US Small Cap Cash Cows 100 ETF 0.46

Vanguard Tax-Managed Small Cap Adm 0.43

Harmony Biosciences Holdings Inc Market Status

Strong Buy: 5

Buy: 3

Hold: 0

Sell: 1

Strong Sell: 0

Harmony Biosciences Holdings Inc Fundamentals

Market Cap 1603.34 M

PB Ratio 1.8484

PE Ratio 10.2288

Enterprise Value 996.87 M

Total Assets 1271.63 M

Volume 1028103

Harmony Biosciences Holdings Inc Company Financials

Annual Revenue FY25:868453000 868.5M, FY24:714734000 714.7M, FY23:541918000 541.9M, FY22:437855000 437.9M, FY21:305440000 305.4M

Annual Profit FY25:670111000 670.1M, FY24:557919000 557.9M, FY23:436949000 436.9M, FY22:354374000 354.4M, FY21:249922000 249.9M

Annual Net worth FY25:158687000 158.7M, FY24:145493000 145.5M, FY23:150755000 150.8M, FY22:181468000 181.5M, FY21:34597000 34.6M

Quarterly Revenue Q4/2025:243776000 243.8M, Q3/2025:239455000 239.5M, Q2/2025:200489000 200.5M, Q1/2025:184733000 184.7M, Q4/2024:201267000 201.3M

Quarterly Profit Q4/2025:175231000 175.2M, Q3/2025:179805000 179.8M, Q2/2025:162336000 162.3M, Q1/2025:152739000 152.7M, Q4/2024:146858000 146.9M

Quarterly Net worth Q4/2025:22486000 22.5M, Q3/2025:50865000 50.9M, Q2/2025:39776000 39.8M, Q1/2025:45560000 45.6M, Q4/2024:49475000 49.5M

About Harmony Biosciences Holdings Inc & investment objective

Company Information Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Organisation Biotechnology

Employees 293

Industry Biotechnology

CEO Dr. Jeffrey M. Dayno M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Harmony Biosciences Holdings Inc FAQs

What is the share price of Harmony Biosciences Holdings Inc today?

The current share price of Harmony Biosciences Holdings Inc is $28.28.

Can I buy Harmony Biosciences Holdings Inc shares in India?

Yes, Indian investors can buy Harmony Biosciences Holdings Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Harmony Biosciences Holdings Inc shares in India?

You can easily invest in Harmony Biosciences Holdings Inc shares from India by:

Can I buy fractional shares of Harmony Biosciences Holdings Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Harmony Biosciences Holdings Inc?

Harmony Biosciences Holdings Inc has a market cap of $1603.34 M.

In which sector does Harmony Biosciences Holdings Inc belong?

Harmony Biosciences Holdings Inc operates in the Biotechnology sector.

What documents are required to invest in Harmony Biosciences Holdings Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Harmony Biosciences Holdings Inc?

The PE ratio of Harmony Biosciences Holdings Inc is 10.23 and the PB ratio is 1.85.